TEXLab, a mathematical AI software created by scientists at Imperial College London and the University of Melbourne can predict survival rates of patients with ovarian cancer more accurately than any current method, a trial published in Nature Communications has found.
Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.
More errors occur in DNA replication during times of stress when resources are scares, scientists at the University of Toronto have found.
Bristol-Myers Squibb (BMS) has announced intentions to buy Celgene for $74bn. This transaction, the fourth largest such deal in pharma history, will give BMS access to several cancer franchises, including experimental cell therapies which attack tumours.
A new AI program can predict the symptoms of a patient’s cancer and their severity of the course of treatment.
Personalised tumour-detecting cells from adult skin cells have been used to shrink brain tumours in mice by up to 5%, scientists have revealed. While the strategy has not yet been fully tested in people, it could in the future give doctors the ability to develop a custom treatment for certain cancer types.
AstraZeneca and Cancer Research UK (CRUK) have announced that they will work together to open a new research centre in the UK, applying CRISPR and other functional genomics technologies to develop new cancer drugs. Specifically, the centre will study how genes and proteins interact with each other in cancer cells, and create disease models using genome-altering technologies based on this.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
A universal test which can detect traces of any cancer in a patient’s bloodstream in ten minutes has been developed by scientists from the University of Queensland. As it stands the test has a sensitivity of 90%, so is able to detect 90 in 100 cases of cancer.
UC San Francisco scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies.
Single nucleotide variations could be the key to better identification of tumour subpopulations
One of the big issues with chemotherapy is that most treatment approaches focus on the tumour itself without paying significant attention to the microenvironment surrounding the tumour. A new method seeks to solve that.
The Novartis CAR-T cell therapy, Kymriah (tisagenlecleucel), will be made available to patients under the age of 25 via the Cancer Drugs Fund.
Scientists have found a cause for the frequent and damaging events in cancer cells’ genetic material where sections of individual chromosomes were broken at a number of points and reassembled wrongly, so entire sections were missing and others were duplicated or incorporated in a wrong orientation.
Microfluidics for use in single cell applications is growing in popularity, as scientists are taking advantage of increasing numbers of commercially available systems enabling high throughput analysis of single cells.